[{"id":"6ea988bc-bcb5-4786-9945-6bf50260a535","acronym":"","url":"https://clinicaltrials.gov/study/NCT06861855","created_at":"2025-09-07T01:51:21.194Z","updated_at":"2025-09-07T01:51:21.194Z","phase":"","brief_title":"Prognosis of METTL-14 in Endometrial Carcinoma","source_id_and_acronym":"NCT06861855","lead_sponsor":"Assiut University","biomarkers":" METTL14","pipe":"","alterations":" ","tags":["METTL14"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-03-06"},{"id":"08b2bc8f-c536-4ab4-95bd-8afe3b23bcd7","acronym":"NRG-GY026","url":"https://clinicaltrials.gov/study/NCT05256225","created_at":"2022-02-25T17:52:52.661Z","updated_at":"2025-02-25T12:28:40.900Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer","source_id_and_acronym":"NCT05256225 - NRG-GY026","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 525","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-24"},{"id":"0cde78dd-3c84-4aec-a573-c0c0e01915a1","acronym":"OPTEC","url":"https://clinicaltrials.gov/study/NCT03460483","created_at":"2021-01-18T17:03:29.688Z","updated_at":"2025-02-25T13:48:28.789Z","phase":"","brief_title":"Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care","source_id_and_acronym":"NCT03460483 - OPTEC","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" MSI • POLE","pipe":" | ","alterations":" POLE mutation","tags":["MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1001","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-20"},{"id":"ed7e0a8d-7121-41ed-982b-5af9f5bc5b3a","acronym":"NRG-GY025","url":"https://clinicaltrials.gov/study/NCT05112601","created_at":"2021-11-09T20:21:18.547Z","updated_at":"2025-02-25T14:16:28.432Z","phase":"Phase 2","brief_title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT05112601 - NRG-GY025","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-18"},{"id":"d94f7980-52bd-4422-b97d-6ffc7470ef49","acronym":"NRG-GY031","url":"https://clinicaltrials.gov/study/NCT05950464","created_at":"2023-07-20T15:09:28.523Z","updated_at":"2025-02-25T14:42:14.385Z","phase":"Phase 1","brief_title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT05950464 - NRG-GY031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694 • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-14"},{"id":"d026d8e4-9c91-4cee-be37-7c17094bbad4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06218914","created_at":"2024-01-23T17:20:10.961Z","updated_at":"2024-07-02T16:34:25.951Z","phase":"Phase 1","brief_title":"A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation","source_id_and_acronym":"NCT06218914","lead_sponsor":"Neogene Therapeutics, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/05/2024","start_date":" 02/05/2024","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 01/02/2040","study_completion_date":" 01/02/2040","last_update_posted":"2024-06-14"},{"id":"413409a2-0792-4de1-a64e-d4d1801140e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586661","created_at":"2021-01-18T17:38:28.376Z","updated_at":"2024-07-02T16:34:27.534Z","phase":"Phase 1","brief_title":"Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03586661","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/29/2019","start_date":" 04/29/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-11"},{"id":"c601c65b-3600-41bd-8dc4-3c6054a931d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04585958","created_at":"2021-01-18T21:52:44.198Z","updated_at":"2024-07-02T16:34:38.039Z","phase":"Phase 1","brief_title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer","source_id_and_acronym":"NCT04585958","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Suspended","enrollment":" Enrollment 55","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-06-05"},{"id":"8c77c515-8fd7-47a1-b2a0-d210db442390","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977574","created_at":"2021-01-18T03:48:50.533Z","updated_at":"2024-07-02T16:35:03.140Z","phase":"Phase 2","brief_title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00977574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1","pipe":"","alterations":" ","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-17"},{"id":"bd3903e4-47f8-44a5-a2e7-496b069f8567","acronym":"","url":"https://clinicaltrials.gov/study/NCT02208375","created_at":"2021-01-18T10:20:36.481Z","updated_at":"2024-07-02T16:35:02.701Z","phase":"Phase 1/2","brief_title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","source_id_and_acronym":"NCT02208375","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/11/2014","start_date":" 11/11/2014","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-05-17"},{"id":"bd7ac170-f9ec-4021-bd06-e5f2697c1c6d","acronym":"ELU-FRα-1","url":"https://clinicaltrials.gov/study/NCT05001282","created_at":"2021-08-11T14:55:40.694Z","updated_at":"2024-07-02T16:35:12.374Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","source_id_and_acronym":"NCT05001282 - ELU-FRα-1","lead_sponsor":"Elucida Oncology","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELU001"],"overall_status":"Recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-28"},{"id":"578ed237-447e-411c-ac2e-ddd1c7129e54","acronym":"OATH","url":"https://clinicaltrials.gov/study/NCT04719273","created_at":"2024-03-13T13:34:11.049Z","updated_at":"2024-07-02T16:35:14.938Z","phase":"Phase 2","brief_title":"Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer","source_id_and_acronym":"NCT04719273 - OATH","lead_sponsor":"Thomas Jefferson University","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • Apristor (onapristone XR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-13"},{"id":"653b0929-1d57-4b2a-adf0-7e0b59367122","acronym":"","url":"https://clinicaltrials.gov/study/NCT02142803","created_at":"2021-01-18T09:57:08.346Z","updated_at":"2024-07-02T16:35:16.708Z","phase":"Phase 1","brief_title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","source_id_and_acronym":"NCT02142803","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • sapanisertib (CB-228) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-01"},{"id":"e41a0274-04d0-4274-aa51-19e90a49274f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983954","created_at":"2021-01-18T19:35:39.578Z","updated_at":"2025-02-25T15:08:38.440Z","phase":"Phase 1","brief_title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03983954","lead_sponsor":"NeoTX Therapeutics Ltd.","biomarkers":" HER-2 • ER • TPBG","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • TPBG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/10/2019","start_date":" 10/10/2019","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-02-22"},{"id":"bf025afb-cb7b-4218-a07e-2e1a6a998168","acronym":"VICTORIA","url":"https://clinicaltrials.gov/study/NCT02730923","created_at":"2021-01-18T13:22:14.129Z","updated_at":"2024-07-02T16:35:19.665Z","phase":"Phase 1/2","brief_title":"Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)","source_id_and_acronym":"NCT02730923 - VICTORIA","lead_sponsor":"Centre Leon Berard","biomarkers":" ER • PGR • ABCB1","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR • ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-13"},{"id":"c5847455-14bd-412e-bc9e-3e7418b191d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03643510","created_at":"2021-01-18T17:53:06.038Z","updated_at":"2024-07-02T16:35:22.709Z","phase":"Phase 2","brief_title":"Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer","source_id_and_acronym":"NCT03643510","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" HR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 08/21/2018","start_date":" 08/21/2018","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-01-22"},{"id":"2dd99279-9ac9-4f3f-9024-0d203f7d34e4","acronym":"NRG-GY014","url":"https://clinicaltrials.gov/study/NCT03348631","created_at":"2021-01-18T16:32:10.163Z","updated_at":"2024-07-02T16:35:29.997Z","phase":"Phase 2","brief_title":"Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer","source_id_and_acronym":"NCT03348631 - NRG-GY014","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ARID1A","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2023-11-08"},{"id":"72fc68c9-215a-40a6-91f6-d9f55c3287fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02020707","created_at":"2021-01-18T09:14:56.657Z","updated_at":"2024-07-02T16:35:35.067Z","phase":"Phase 1","brief_title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","source_id_and_acronym":"NCT02020707","lead_sponsor":"Mayo Clinic","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 02/24/2014","start_date":" 02/24/2014","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-10-02"},{"id":"98f9903f-5399-470c-a4e4-810aaee0f5a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681248","created_at":"2022-08-29T14:58:12.640Z","updated_at":"2024-07-02T16:35:35.195Z","phase":"","brief_title":"Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT04681248","lead_sponsor":"Leap Therapeutics, Inc.","biomarkers":" RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":"","alterations":" ","tags":["RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirexatamab (DKN-01)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-09-29"},{"id":"6a195d42-7b84-44ce-9a77-cbfcd817be1c","acronym":"KEYNOTE-868","url":"https://clinicaltrials.gov/study/NCT03914612","created_at":"2021-01-18T19:16:25.580Z","updated_at":"2024-07-02T16:35:47.936Z","phase":"Phase 3","brief_title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT03914612 - KEYNOTE-868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 759","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 12/16/2022","primary_completion_date":" 12/16/2022","study_txt":" Completion: 05/10/2024","study_completion_date":" 05/10/2024","last_update_posted":"2023-05-16"},{"id":"1f4f5746-c34c-4d2d-b0f5-a6c669df68bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02874430","created_at":"2021-01-18T14:06:47.451Z","updated_at":"2024-07-02T16:35:59.056Z","phase":"Phase 2","brief_title":"Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer","source_id_and_acronym":"NCT02874430","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" HER-2 • ER • PGR • CAV1 • SLC16A1","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • CAV1 • SLC16A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/08/2016","start_date":" 06/08/2016","primary_txt":" Primary completion: 12/02/2020","primary_completion_date":" 12/02/2020","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-12-15"},{"id":"fa288c29-592d-4dfb-ba55-267713dd3131","acronym":"DUET-2","url":"https://clinicaltrials.gov/study/NCT03517488","created_at":"2021-01-18T17:18:50.722Z","updated_at":"2024-07-02T16:35:59.763Z","phase":"Phase 1","brief_title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","source_id_and_acronym":"NCT03517488 - DUET-2","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2022-12-01"},{"id":"789a1736-ad24-4164-869f-53be93217e9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04873206","created_at":"2021-05-05T11:52:35.340Z","updated_at":"2024-07-02T16:36:07.266Z","phase":"","brief_title":"Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies","source_id_and_acronym":"NCT04873206","lead_sponsor":"Sohag University","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2022-07-15"},{"id":"50472ebf-13f3-4a6d-abc3-8b39f9bfd5ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04611139","created_at":"2021-01-19T20:32:44.176Z","updated_at":"2025-02-25T16:10:47.159Z","phase":"Phase 1","brief_title":"Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers","source_id_and_acronym":"NCT04611139","lead_sponsor":"HonorHealth Research Institute","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • seclidemstat (SP2577)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-03-01"}]